Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

2019145 citationsJournal Articlebronze Open Access

Authors

Francesca Palandri · IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola

Massimo Breccia · Sapienza University of Rome

Massimiliano Bonifacio · University of Verona

Nicola Polverelli · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Elena Maria Elli · Azienda Ospedaliera San Gerardo

Giulia Benevolo · CTO Hospital

Mario Tiribelli

Abstract

The survival of patients with myelofibrosis after discontinuation of ruxolitinib is poor, particularly for those who discontinue in blast phase. Salvage therapies can improve outcome, emphasizing the need for novel therapies.

Topics & Keywords

Myeloproliferative Neoplasms: Diagnosis and Treatment Acute Myeloid Leukemia Research Chronic Myeloid Leukemia Treatments

UN Sustainable Development Goals

No poverty

Publication Details

Published in: Cancer

Volume 126, Issue 6, pp. 1243-1252

DOI: 10.1002/cncr.32664

Field-Weighted Citation Impact: 9.84